- Sarepta Therapeutics Inc (NASDAQ:SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone promises.
- Under the agreement, Sarepta will have the rights to five neuromuscular and cardiac indications, including Duchenne muscular dystrophy.
- According to Sarepta, the deal covers the MyoAAV program that aims to deliver more efficient gene therapies and at lower doses using modified capsids.
- Also Read: Sarepta’s Duchenne Gene Therapy Update Gets Bullish Stance From Analysts.
- Delivered 25-50 times greater gene expression in multiple skeletal muscles and 10-15 times greater gene expression in cardiac muscle;
- Demonstrated reduced delivery to the liver by 50% and showed lower accumulation in the liver.
- Due to increased efficiency, it can be used at up to a log lower dose than traditional AAV vectors.
- Full research for MyoAAV in a Duchenne mouse model was published in Cell in 2021. Sarepta CEO Doug Ingram said the viruses could “substantially reduce viral load,” while CSO Louise Rodino-Klapac touted the platform’s “broad applicability.”
- Price Action: SRPT shares are up 3.17% at $109.38 during the market session on the last check Monday.
Stephens & Co. Maintains Equal-Weight on Norfolk Southern, Raises Price Target to $230
Stephens & Co. analyst Justin Long maintains Norfolk Southern (NYSE:NSC) with a Equal-Weight and raises the price target from $225 to $230.
